



2026 PCPA CANCER SUMMIT

**Delivering Tomorrow's Cancer Care
in Today's Private Practice:**
Strategies, Innovations and Outcomes

Conference Program

Platinum Sponsor

abbvie

W Hotel - Melbourne Australia
28 - 29 August 2026

FOREWORD



Dear Partners and Colleagues,

Cancer care is changing rapidly. Genomics, AI, ctDNA, advanced radiation, cellular therapies and targeted treatments are expanding what is possible for patients—but innovation only matters when it can be translated into timely, equitable, sustainable treatment and care.

That is the central question of the 2026 PCPA Cancer Summit: how do we deliver tomorrow's cancer care in today's private practice?

Across the program, we will examine the practical conditions needed to turn new science into better care: funding and access, workforce capability, research, data, collaboration and strong public–private partnerships. We will explore AI and the future specialist clinic, precision oncology and co-dependent genomic testing, advanced therapies including CAR-T, tumour-stream innovation, and the reforms needed to make access pathways more responsive to modern cancer care.

We will also confront the realities faced by patients, clinicians and services: financial toxicity, fragmented pathways, delayed access and the challenge of delivering complex care close to home. Importantly, the Summit will keep the patient and family experience at its centre, recognising that high-quality cancer care depends not only on clinical excellence, but also on communication, connection, dignity and trust.

PCPA's role is to strengthen private cancer care through advocacy, leadership, mentorship and collaboration. Private and public services are interdependent, and neither can meet Australia's growing cancer burden alone. This Summit is an opportunity to work together, across clinical practice, policy, research, industry and consumer advocacy, to shape a cancer system that is future-ready, sustainable and patient-centred.

Thank you for joining us in Melbourne. We look forward to the conversations, partnerships and practical actions that will follow.

A handwritten signature in black ink, appearing to read 'Chris Steer'.

Warm regards,
A/Professor Christopher Steer
President, Private Cancer Physicians of Australia

OUR STRATEGIC VISION

Our Purpose

PCPA exists to strengthen the private cancer care sector by advocating for private cancer clinicians, supporting them at every stage of their career, and enabling them to provide excellence in cancer care for their patients.

Our Ambition

To be the trusted voice for private cancer care – shaping policy, fostering strategic partnerships, and ensuring the sector's long-term financial sustainability, so the PCPA can continue to deliver world-class outcomes for patients.



PCPA ACHIEVEMENTS



Our Outcomes

Since 2007, the Private Cancer Physicians of Australia (PCPA) has been a high impact peak body that advocates for cancer patients. The medical oncologists, haematologists and radiation oncologists who are our members and care for Australian cancer patients within the private healthcare system, want to ensure the ecosystem remains robust and resilient.

Our work has never been more important. We need your help to ensure the cancer patient voice in Canberra and those that treat them, is heard and actioned.

Together with our patient advocacy groups and clinical stakeholders, we lead the engagement with the nation's decision-makers to ensure they prioritise the needs of Australians living with cancer. Recent examples of our work include:

- PCPA delegate at the Parliament House roundtable to advocate for a Bridging Fund Coalition
- Leading the engagement regarding the Inquiry into Specialist fees with our active Canberra program
- PCPA involvement in the Senate Community Affairs inquiry into treatment access for rare cancers, with a joint submission across Cancer Council Australia, MOGA, COSA and CNSA
- The formation of the PCPA Cellular Therapies Alliance (CTA), will drive our haematology focus and advocacy for access to CART-cell therapies in the private sector is achieved
- Expanding access to key oncology medicines and genomics
- Voicing our need for transparency and action in accelerating the approval of medicines and diagnostics through improved HTA process
- Advocating for bipartisan support for policies aimed at reducing the financial toxicity of the cancer patients' treatment journey
- Seeking (& being granted) an extension of 6 months for MBS item numbers for TeleHealth for patients requiring phone consults with their specialists during the COVID19 pandemic.
- Ensuring cancer patient navigators are front and centre of the National Cancer Plan
- Ring-fencing cancer patients – and their chemotherapy treatments – from the Special Pricing Arrangement (SPA) reforms
- Extending MBS to subcutaneous chemotherapy treatments
- Achieving our key objectives for cancer patients out of the long-running MBS review

We have worked hard to harness funding and meaningful policy outcomes and our track record is reflected in our high political capital with all sides of politics.

SUMMIT CONVENORS

This Summit has been shaped by the generosity, expertise and commitment of our Education Chair and Meeting Convenors. Their guidance has helped create a program that is practical, forward-looking and grounded in what matters most to patients, clinicians and the future of private cancer care.

We sincerely thank them for their leadership and contribution.

**Secretary & Chair of Education**

Professor Stephen Clarke OAM
Medical Oncologist,
Director of Cancer Services for the NSLHD
Professor of Medicine at the University of Sydney.

**VIC State Director**

Dr Cameron McLaren
Medical Oncologist,
St John of God, Berwick

**Emerging Leaders Director**

Dr Amy Davies
Medical Oncologist
Epworth Freemasons & SJOG Bendigo

**Haematology Director**

Assoc Professor Costas Yannakou
Clinical Haematologist
Epworth HealthCare

FRIDAY 28 AUGUST 2026

Time		Speaker
5.00-7.00pm	Connections & Conversations - meet with all attendees	Curious Bar, W Hotel
7.30pm	Members and Speakers dinner	

SATURDAY 29 AUGUST 2026 - The Great Room

Time	Topic	Speaker
Breakfast Session 7.30-8:45am	<i>Building an Innovative Career in Private Cancer Care: Medical Oncology, Haematology, Radiation Oncology</i> <i>Financial & Legal considerations when setting up your practice</i> <i>Expert Panel</i>	<i>Chairs:</i> <i>Dr Paul Viray & Dr Prachi Bhawe</i> <i>Mr Craig Meade,</i> <i>Dr Ian Irving, Dr Amy Davies,</i> <i>Dr Vinod Ganju, Dr Marcus Foo,</i> <i>Dr Belle Sasse</i>
	<i>Delivering Tomorrow's Cancer Care in Today's Private Practice – Strategies, Innovations and Outcomes</i>	
9.00am	Official Opening	Chair: Assoc Prof Christopher Steer
9.10am	Political Addresses from both sides of the aisle Senator Michelle Ananda-Rajah Senator the Hon Anne Ruston	Chair: Dr Ian Irving
9.35am	<i>Australian Cancer Plan and Policy Context</i>	<i>Chair: Assoc Professor Christopher Steer</i>
9.35am	Keynote: The Australian Cancer Plan – implications for innovation and equity	Professor Dorothy Keefe
9.55am	Audience Q&A: Implications for Private Practice	All
10.05am	<i>Innovation in Real-World Private Practice</i>	<i>Chair: Professor Desmond Yip</i>
10.05am	Plenary 1: The future of the AI specialist clinic in ANZ	Dr Daniel Cheng
10.23am	Plenary 2: Genomics, ctDNA and molecular profiling	Professor Jeanne Tie
10.41am	Plenary 3: The role of SABR in metastatic cancers	Professor Shankar Siva
11.00am	Coffee break	

Our Strategic Vision

We aim to be the trusted voice for cancer care. By shaping policy, fostering strategic partnerships, and ensuring the long-term financial sustainability of the sector, the PCPA can continue to provide worldclass outcomes for patients.

Through education, mentorship, and advocacy, the PCPA aims to create a vibrant and thriving membership community that clinicians see as indispensable to their careers. The PCPA does so while expanding our impact and presence within the healthcare ecosystem.

SATURDAY 29 AUGUST 2026 - The Great Room

Time	Topic	Speaker
11.20am	<i>Central Block – Reform, Access and Sustainability in Private Cancer Care</i>	
	<i>Part 1: Re-engineering Access and HTA</i>	<i>Chair: Dr Anu Agarwal</i>
11.20am	Keynote: Re-engineering Access and HTA for Private Oncology	Professor Robyn Ward AM
11.45am	Expert Panel Discussion	Professor Robyn Ward Assoc Professor Christopher Steer Assoc Professor Colman Taylor Ms Vicki Durston Ms Nathalie McNeil Dr Erin Evans
12.10pm	<i>Part 2: Private Practice Sustainability Forum</i>	<i>Chair: Professor Stephen Clarke OAM</i>
12.10pm	Keynote: Private Practice Sustainability: Challenges and Opportunities	Ms Christine Gee AM
12.30pm	Expert Panel Discussion	Ms Christine Gee Professor Gary Richardson OAM Ms Lisa Norman Professor Grant McArthur AO Professor Zanfina Ademi Mr Matthew Bellairs Mr Harry Thomas
1.00pm	Lunch	
1.45pm	<i>Presidential Transition</i>	<i>Professor Desmond Yip</i>
2.00pm	<i>Story, Communication and Patient Voice</i>	<i>Chair: Dr Cameron McLaren</i>
2.00pm	Keynote: "Because I Loved You"	Ms Stephanie Duran
2.20pm	Consumer Panel discussion	Michelle and Judith
2.45pm	<i>Innovation Across Tumour Streams</i>	<i>Chair: Dr Amy Davies</i>
2.45pm	Spotlight 1: Biomarkers, Access and Sequencing: Real-World Choices in Breast Cancer.	Assoc Professor Yoland Antill
3.05pm	Spotlight 2: Up front treatment sequencing in CLL in 2026	Assoc Professor Mary Ann Anderson
3.25pm	Spotlight 3: GI Cancer Care in 2026: Navigating Biomarkers, Sequencing and Access	Dr James McCracken
3.45pm	Afternoon Tea	
4.05pm	<i>Emerging Leaders - Our Future</i>	<i>Chair: Dr Belle Sasse</i>
4.05pm	Beyond RCTs: How Real-World Registries Are Refining Cancer Care Investigator, Collaborator, Mentor-building research into private practice The Missing Ingredient: Why the future of CAR-T depends on people not platforms	Dr Matthew Loft Dr Shehara Mendis Dominic Fernandez
4.50-5.00pm	<i>Summit Close</i>	<i>Dr Cameron McLaren</i>



Professor Zanfina Ademi

Professor Zanfina Ademi is Professor of Health Economics and Head of the Health Economics and Policy Evaluation Research (HEPER) Group at Monash University's Centre for Medicine Use and Safety. Her research focuses on health technology assessment, economic evaluation and decision-analytic modelling to inform healthcare policy and reimbursement decisions. She has led numerous national and international studies across cancer, cardiovascular disease and genomics, with a particular interest in evaluating the value of innovative healthcare interventions. Professor Ademi serves on Australia's Pharmaceutical Benefits Advisory Committee (PBAC) Economics Sub-Committee and is committed to translating research into evidence that improves health policy and patient outcomes.



Dr Anu Agarwal

Dr Anupriya Agarwal is a medical oncologist with appointment at the Mater Hospital in Sydney. Dr Agarwal specialises in breast and gastrointestinal cancers, with active research into patient physician communication and the financial impacts of cancer care. She holds a PhD from the University of Sydney and has previously worked as a Medical Advisor at Cancer Australia, providing strategic input to national cancer policy.

She contributes to national drug approval panels, mentors postgraduates, and holds a Clinical Senior Lecturer position at the University of Sydney.



Senator Michelle Ananda-Rajah

Dr Michelle Ananda-Rajah is a Victorian Senator and former infectious diseases and general medicine physician with 26 years' experience at The Alfred Hospital. Prior to her election to the Senate in 2025, Michelle was elected to the lower house as the Member for Higgins in 2022. She holds a PhD from the University of Melbourne and was an award-winning medical researcher and Associate Professor at Monash University. Drawing on her frontline clinical and research experience, Michelle is a strong advocate for evidence-based healthcare, medical research, and policies that improve outcomes for patients, including those affected by cancer.



Associate Professor Mary Anne Anderson

Associate Professor Anderson has been a practising clinical haematologist since 2012. She currently practices both at The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre in Melbourne where she leads the Low-Grade Lymphoma and Chronic Lymphocytic Leukaemia Disease Stream. She is a foundation member of the CART consultant group at the Peter MacCallum Cancer Centre having joined the team at the inception of the unit in 2019. Dr Anderson obtained her PhD from the University of Melbourne in 2017 where she undertook extensive clinical and laboratory studies of a novel approach to treating B cell malignancies by harnessing apoptotic cell death with the agent now known as venetoclax. Since completion of her PhD Dr Anderson has continued her studies into mechanisms by which B cell malignancies evade targeted agents to develop therapeutic resistance.



Associate Professor Yoland Antill

Associate Professor Yoland Antill works as a Medical Oncologist and as a Cancer Genetics specialist within the public and private sector in Melbourne with over 20 years of experience in each discipline. Her working and research interests are in the management of Breast and Gynaecological cancers together with Hereditary Cancer Syndromes. She is the current chair of ANZGOG's Uterine Tumour working Group and a member of their Research Advisory Committee. Additionally she has advisory roles with Breast Cancer Network of Australia, Ovarian Cancer Australia as well as a number of Industry related boards. Yoland is the lead investigator for a number of local and international research studies and is involved in the development and conduct of clinical and supportive care trials and has published extensively within peer review journals.



Mr Matthew Bellairs

Matthew Bellairs is Chief Operating Officer at GenesisCare Australia, one of the country's leading providers of integrated cancer care. With more than 20 years' experience in healthcare management, Matthew brings deep expertise across oncology, medical imaging and cardiology, with a strong focus on operational excellence, sustainable growth and innovation in patient-centred care. Since joining GenesisCare in 2024, he has played a key role in advancing strategies that support doctors and strengthen the delivery of high-quality cancer care to more than 35,000 patients annually.





Dr Prachi Bhave

Dr Prachi Bhave is a Medical Oncologist and leads the Early Phase Oncology Clinical Trials Program at Cabrini. Dr. Bhave oversees the screening, enrolment and management of oncology patients with end stage cancer participating in early phase clinical trials. The trials program at Cabrini is robust and varied, involving several new and exciting therapies for treatment refractory solid organ malignancies. Through the incorporation of a patient's genomic profile, patients are matched to clinical trials that best suit their mutational profile, reflecting a personalised treatment approach that is of vital importance in the current era of precision medicine. Outside of Cabrini, Dr Bhave is completing a PhD in genomics and computational biology at WEHI and Peter MacCallum Cancer Centre. Dr Bhave has a strong interest in translational research and has a special interest in early drug development, skin and gynaecological malignancies.



Ms Michelle Casey

Michelle Casey is a patient advocate and speaker whose journey has been shaped by extraordinary challenges and recovery. Following a serious motorcycle accident in 2023 that resulted in significant physical injuries, Michelle was subsequently diagnosed with Stage 4 Mantle Cell Lymphoma in 2024 and underwent an allogeneic donor stem cell transplant. Now 1 year post transplant, Michelle shares her lived experience with medical audiences, offering a positive perspective on resilience, recovery and seeing the person beyond the diagnosis. Michelle's story is one of strength, hope and choosing to thrive not simply survive.



Dr Daniel Cheng

Dr Daniel Cheng is currently an anaesthetic registrar at Royal North Shore Hospital and the lead clinician in Medow's AI team. Daniel started his career in corporate finance before pivoting to studying medicine at the University of Sydney. He has studied and worked in several hospitals including Royal North Shore, North Shore Private Hospital, Northern Beaches Hospital, Port Macquarie Base Hospital and Orange Hospital, and these experiences have helped him develop a deep understanding of healthcare and the hospital sector. Through his interactions with a broad range of specialists as part of his hospital work, Daniel is also very aware of the day to day needs of clinicians and is passionate about Medow Health's mission to allow specialists to focus less on documentation and more on their patients.



Professor Stephen Clarke

Stephen Clarke is a medical oncologist at Royal North Shore Hospital in Sydney and Professor of Medicine at the University of Sydney. He is the Director of the North Star VNP Cancer Trials Unit in Northern Sydney Local Health District. After completing his medical oncology training at Royal North Shore Hospital, Stephen undertook a PhD in the Phase I trials unit of the Institute of Cancer Research/Royal Marsden Cancer Hospital, before returning to Australia in 1994. He has clinical and research interests in thoracic and GI cancers, including mesothelioma. His research has achieved over \$30 million in competitive grant funding that has led to over 400 publications with a Google Scholar Impact Factor of 85. He was included in the top 2% of cited researchers in the world in 2024.

His work has been recognized by an Order of Australia Medal (OAM) in 2011, the Medical Oncology Group of Australia (MOGA) Cancer Achievement Award in 2016 and the Eric Susman Prize (2013), the College Medal (2019) and John Sands Medal (2020) from the Royal Australasian College of Physicians.



Ms Judith Culliver

I was diagnosed with bilateral stage 3 breast cancer in 2020 so much of my treatment was during Covid. In 2025, I developed a local recurrence and started oral chemotherapy with good results. I retired in March 2024 having worked as a GP for forty years in northeast Melbourne.

From about 1990, I also worked as a medical educator with students, registrars and GP supervisors with a special interest in clinical and communication skills. My final work was for the RACGP developing educational material.

I enjoy sport, cooking, reading and travel and in my retirement, I have been able to continue these to a greater extent. More recently as well as running and tennis, I have added Pickleball to the list of sports I participate in. Most importantly, I have a husband, two sons at home, and two stepchildren both of whom are married with children.



Dr Amy Davies

Dr Amy Davies is a Medical Oncologist based in Victoria, with expertise in breast cancer, neuro-oncology, and molecular oncology. She holds degrees in Clinical Sciences, Medicine/Surgery, Public Health, and Internal Medicine, and is a Fellow of the Royal Australasian College of Physicians. Amy works at Epworth and St John of God Bendigo and Bendigo Health. She treats a wide range of solid organ malignancies and is an active participant in clinical research and cancer genomics. Amy is the Director of the Emerging Leaders Board of the Private Cancer Physicians of Australia.



Ms Stephanie Duran

Stephanie Duran is an international keynote speaker, author of *Because I Loved You*, certified grief and loss coach, and former trial lawyer who brings a deeply human perspective to the medical and caregiving space. After a successful legal career and as a law professor, her life shifted profoundly when her husband was diagnosed with terminal cancer. Through caregiving and supporting his decision to die with dignity, Stephanie experienced firsthand the emotional complexities patients, families, and providers navigate.

Today, she works with healthcare professionals to bridge the gap between clinical care and human connection. Blending advocacy expertise with lived experience, she offers insight into the unspoken needs of patients and families facing serious illness, end-of-life decisions, and what comes after. Her work empowers providers to communicate with greater presence, compassion, and clarity, supporting not just treatment, but the human experience behind it, including grief and the courage to rebuild after.



Ms Vicki Durston

Vicki Durston is Director, Policy, Advocacy & Support Services at Breast Cancer Network Australia (BCNA), leading national policy and advocacy initiatives to improve outcomes for Australians affected by breast cancer. She has more than 30 years' experience across nursing, health administration, management, and leadership, specialising in breast cancer across both public and private healthcare settings in Australia.

Vicki informs health policy, drives system reform, and amplifies consumer voices at state, national, and international levels. She has held multiple board positions and currently serves as President of the General Assembly for the Advanced Breast Cancer Global Alliance, contributing to international collaboration to improve outcomes for people living with metastatic breast cancer.

Vicki combines strategic leadership and executive expertise with a deep commitment to driving equity, collaboration, and lasting improvements in cancer care and policy.



Dr Erin Evans

Dr Erin Evans is the Chief Executive Officer of InGeNA, Australia's national peak body for genomics and precision medicine. She leads national collaboration and advocacy to accelerate the adoption of genomics into healthcare through policy reform, industry partnerships and health system innovation.

Erin holds a PhD in Biotechnology from the University of Queensland and has built a career spanning research translation, commercialisation and health system transformation. She has held senior international leadership roles in biotechnology and pharmaceuticals, including with Sanofi, before leading the life sciences sector in Queensland and then genomics and precision medicine sector nationally.

Erin is a member of the Genomics Australia Advisory Council and is the former Chair of the Queensland Genomics Advisory Board and Health Consumers Queensland. She has extensive experience advising governments, health services and industry on genomics implementation, patient-centred policy and system transformation. She also mentors emerging life sciences companies through CSIRO's national accelerator programs.



Mr Dominic Fernandez

Dominic Fernandez is an experienced biopharmaceutical and scientific leader with experience spanning healthcare, pharma and advanced therapies. A trained clinical cardiovascular perfusionist and medical scientist with an MBA, he has held pivotal roles at leading organisations such as the Royal Children's Hospital, Novartis and Johnson & Johnson. He currently serves as the Scientific Lead for Cell Therapy and Immunotherapy at Epworth HealthCare in Melbourne, where he is leading the development of Australia's first philanthropically funded CAR-T program.

Dominic's work focuses on building capacity for advanced therapies in Australia, combining clinical innovation with sustainable workforce and commercial models to improve patient access to advanced therapies. His leadership extends across the full translational spectrum, from process development and regulatory strategy to public-private partnerships, government engagement, and early biotech spinout planning. In addition to his leadership, Dominic is undertaking research at the Murdoch Children's Research Institute focused on identifying workforce barriers and enablers critical to the sustainable delivery of advanced therapies in Australia. He has also been actively involved in developing national frameworks for advanced therapies, collaborating with industry partners, healthcare institutions, and government bodies to shape Australia's future capabilities in cell and gene therapy. Dominic brings deep expertise in building collaborative, cross-sector partnerships and remains a passionate advocate for ensuring that next-generation therapies are accessible to Australian patients through innovative delivery models.



Dr Marcus Foo

Dr Marcus Foo graduated from the University of Melbourne in 2000 and trained in radiation oncology at the Peter MacCallum Cancer Centre. He then undertook a Clinical and Research Fellowship at the BC Cancer Agency in Vancouver, Canada. His clinical interests included gastro-intestinal (GI), breast, and genito-urinary oncology. At this time he was also principal and co-investigator in research projects in anal cancer and prostate cancer plus a prospective phase II trial about radiation therapy techniques for multiple brain metastases.

He subsequently returned to the Peter MacCallum Cancer Centre in Melbourne as a consultant radiation oncologist in the GI/Sarcoma team, prior to joining GenesisCare in 2014.

He consults at the GenesisCare centres in Frankston, Peninsula Private and St John of God, Berwick

Marcus has a clinical research interest in gastro-intestinal cancers and has published in international and national peer-reviewed journals. He has further interests in types of radiation therapy technologies such as stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT).



Associate Professor Vinod Ganju

A/Prof Vinod Ganju graduated in Medicine at the University of Western Australia. He trained in Medical Oncology in Perth and subsequently completed a Fellowship in Haematology and Oncology at the Mayo Clinic in the USA. He is a Fellow of the Royal Australasian College of Physicians as well as being an active member of the American Society of Clinical Oncology, the Medical Oncology Group of Australia, The Haematology Society of Australia & New Zealand, European Society of Medical Oncology and the American Association for Cancer Research.

A/Prof Ganju treats a broad range of cancers and has been consulting on the Peninsula for over 30 years. He was seconded from Peter Mac to set up a new cancer service on the Peninsula and worked at Peninsula Health and Monash Health for many years later went on to set up a cancer unit in the private setting.

He currently works as a clinician and managing Director of Peninsula and Southeast Oncology (PASO) an integrated service involving consulting, multidisciplinary review, day infusion centre and a clinical trials programme. He continues to work at Peninsula Health as a visiting medical officer.

A/Prof Ganju is keenly involved in both national and international clinical trials and multiple translational research programs. At PASO, A/Prof Ganju is the principal investigator for a number of PASO's clinical trials, with research interests in Lung Cancer, Breast Cancer and Early phase clinical trials.



Ms Christine Gee AM

Ms Christine Gee AM is the National President of the Australian Private Hospitals Association and is the Psychiatric Hospital representative on its Council. She has extensive experience in private hospital administration, having held executive management positions for more than 30 years. Christine held the position of CEO of the Toowong Private Hospital, an authorised private psychiatric hospital in Brisbane, Queensland from September 1996 until her appointment as Director, Ramsay Mental Health Australia in March 2025. She is involved in several state and national boards and committees. Christine is longstanding Board member of the Australian Commission for Safety and Quality in Health Care and Chairs its Private Hospital Sector Committee, and Co-chairs its Mental Health Advisory Group. She is a member of the Medical Board of Australia (MBA) and is the Chair of the MBA's National Special Issues Committee (Sexual boundaries and family violence). Christine was the 2021 recipient of the Gold Medal of the Australian Council on Healthcare Standards, and she was appointed a Member (AM) of the Order of Australia (General Division) on 12 June 2023.



Icon
CANCER CENTRE

Dr Ian Irving

Dr Ian Irving is Icon's Chief Medical Officer, an Executive Director of Icon Group and a clinical haematologist, practicing at Icon Wesley and Mackay in Queensland. His clinical practice covers a broad range of haematological disorders including bone marrow transplantation and he is an examiner on the RACP national examination panel. He has sat on national and international committees and advisory boards and has post-graduate qualifications including AFRACMA and GAICD. A strong advocate for clinical trials, medical education, and regional cancer care, Dr Irving combines medical leadership with ongoing patient care and mentoring of young clinicians with him being awarded the 2024 HSANZ for mentorship. He is the QLD State Director of the Private Cancer Physicians of Australia.





Professor Dorothy Keefe

Professor Dorothy Keefe is Chief Executive Officer of Cancer Australia, Australia's national cancer agency. She is an academic medical oncologist with experience spanning clinical medicine, cancer research, health policy and system reform. She provides national leadership in cancer control and advises the Australian Government on strategies to improve outcomes, reduce health inequities and strengthen evidence-based, patient-centred care across the cancer continuum. Professor Keefe has held senior leadership roles across government, health services and academia, including leading major state and national health reform initiatives. She is an internationally recognised authority in cancer supportive care, with more than 200 peer-reviewed publications and extensive experience in clinical guideline development and translational research. She is the current Chair of the Governing Council of the International Agency for Research on Cancer.



Dr Matthew Loft

Dr Matthew Loft is a Medical Oncologist working in both public and private health care. With an additional degree in Pharmacy, and a recently completed PhD in colorectal cancer, he has a unique perspective to clinical practice, anti-cancer therapeutics and research.

He is the current Cancer Services Craft Group and Strategic Lead at Cabrini Health, and alongside clinical practice, he works at the Walter and Eliza Hall Institute, Monash and Melbourne University, combining extensive teaching with the passion of shifting cancer care from generic approaches, to treatments that meet the individual needs of each patient.



Professor Grant McArthur AO

Professor Grant McArthur AO is a Fellow of the Royal Australasian College of Physicians and holds a Ph.D. in Medical Biology. He is the inaugural Lorenzo Galli Chair of Melanoma and Skin Cancers at the University of Melbourne. He is an Associate Editor for the Journal of Clinical Oncology. Professor McArthur is also Head of the Molecular Oncology Laboratory and a Senior Consultant Medical Oncologist at the Peter MacCallum Cancer Centre.

He has published over 350 papers and has served as a national and international chair for multiple clinical trials on targeted therapies and immunotherapies. His research interests include melanoma, clinical trials of targeted therapeutics, the discovery of novel drug targets in cancer, oncogene targeting, the immunological effects of targeted therapies, personalized medicine, and cancer metabolism.



Dr James McCracken

Dr James McCracken is a Melbourne-based Medical Oncologist at Epworth HealthCare with expertise in breast, gastrointestinal and lung cancers. He is committed to compassionate, patient-centred and evidence-based care, with experience in complex cancer therapeutics and clinical trials.

He completed his medical degree at the Australian National University, where he won the leadership prize in his graduating year. He undertook physician training at the Royal Melbourne Hospital, and specialist oncology training through the Victorian Medical Oncology Training Group, where he was co-President. He subsequently completed a fellowship in Breast and Gastrointestinal Oncology and Clinical Trials at the Olivia Newton-John Cancer Research Institute.

Dr McCracken's research interests include breast cancer genomics, circulating tumour DNA and precision-oncology biomarkers.



Dr Cam McLaren

Dr Cameron McLaren is a medical oncologist based in Berwick, Victoria, with subspecialty interests in breast, genitourinary, gastrointestinal, and lung cancers. He completed his oncology training through Peninsula Health, Monash Health, and the Peter MacCallum Cancer Centre, and has been practicing at St John of God Hospital since 2018. Dr McLaren prioritises rapid appointments and clear communication with patients and is deeply involved in clinical trials and end-of-life care, including Victoria's Voluntary Assisted Dying program. He is the current Victorian State Director of the Private Cancer Physicians of Australia.



Ms Nathalie McNeil

Nathalie McNeil (Nat) is the Vice President and General Manager of AbbVie, Australia and New Zealand, leading a combined team of more than 480 employees. Nat has more than 25 years' experience in the healthcare sector, both locally and internationally. She started her career as a pharmacist and since this time has held roles within the pharmaceutical industry across medical, sales and marketing, business development and strategy, and human resources.

Nat joined Allergan in 2019, prior to the integration with AbbVie, as Associate Vice President and General Manager, having previously held a series of executive level roles for multinational healthcare companies, including J&J, Novartis and Pfizer. As a people leader for over 15 years, Nat is most passionate about developing people in service of achieving their aspirations and driving a high performing, results-oriented and positive culture. Nat is also described by colleagues as a leader with an unrelenting commitment to diversity and inclusion. Nat received her Bachelor of Pharmacy from the University of Sydney and is a Graduate Member of the Australian Institute of Company Directors.



Mr Craig Meade

Craig is Tax Principal at DPM. Craig is a Certified Practising Accountant and a Fellow of the Taxation Institute of Australia. He is a specialist in managing the unique needs of the medical profession. Craig advises his client base of high net worth professionals on taxation, structuring, investments, retirement planning, asset protection and finance.



Dr Shehara Mendis

Dr Shehara Mendis is a medical oncologist working with the Oncology Clinical Trials Program at Cabrini Health, specifically focusing on upper and lower gastrointestinal trials. She is passionate about providing empathic, patient-centred care and getting patients onto clinical trials.

Shehara also works with Cabrini's Department of Surgery's Research Team to harness natural synergies between oncological and surgical research programs. Shehara has been involved in the development and implementation of a cell-free DNA collection protocol for upper GI tract cancers while completing a Canadian fellowship, translational research in upper and lower GI tumours within a whole genome sequencing program, as well as clinical outcomes research and quality improvement in clinical trials.



Ms Lisa Norman

Ms Lisa Norman has been in executive-level healthcare roles since 2002. She has worked for St John of God Health Care since July 2006 and, in 2020, was appointed as the Chief Executive Officer of three hospitals in South East Melbourne.

As the CEO of St John of God Berwick Hospital, she led a \$140M project to construct, commission and relocate the hospital in 2018.

Lisa graduated as a registered nurse in 1990 and went on to gain postgraduate qualifications in critical care, specialising in emergency and trauma nursing. She also holds a Graduate Certificate in Catholic Leadership and Culture.

Lisa has interest and experience in Clinical Governance to ensure delivery of safe clinical care and optimising the patient experience.

Lisa is a Director at the St John of God Foundation Board and the Federation University Health Strategic Advisory Board.



Professor Gary Richardson

Professor Gary Richardson is an academic medical oncologist treating gynaecological, gastro-intestinal, breast and lung cancers at Cabrini Hospital in Malvern and Brighton. He is responsible for the clinical trials program and translational research at Cabrini.

Gary is the Group Director of the Cabrini Research and am appointed to the Neil Beaglehall Endowed Chair of Medical Oncology Research. He is principal investigator in many clinical studies in lung and gynaecological malignancy, as well as development of novel compounds for the treatment of cancer (Precision Medicine).

Gary is also Professor of Medicine at Monash University and work with the Monash University Biomedicine Discovery Institute. He is past Chairman of the Medical Oncology Group of Australia and past President of the Private Cancer Physicians of Australia and belongs to multiple national and international research organisations.



Senator the Hon Anne Ruston

Senator Ruston is the Shadow Minister for Health and Aged Care, Deputy Leader of the Opposition in the Senate and Senator for South Australia. Prior to becoming a Senator, Anne held several senior positions in government and the private sector, including as the inaugural chief executive of the National Wine Centre. She was also a primary producer and irrigator, owning and operating the largest commercial rose garden in Australia.

Senator Ruston was appointed Assistant Minister of Agriculture and Water Resources in September 2015. She was subsequently appointed as Assistant Minister for International Development and the Pacific in August 2018. Prior to the 2022 election, Senator Ruston was a Cabinet Minister, holding the positions of Minister for Families and Social Services, Minister for Women's Safety and Manager of Government Business in the Senate for three years.

Born and raised in Renmark, on the River Murray in South Australia, Anne continues to have a strong connection with the Riverland community. She is passionate about regional South Australia and is the only SA Senator who maintains a regional electorate office.



Dr Belle Sassé

Dr Belle Sassé is a medical oncologist working as a locum across Australia, with interests in breast cancer, advocacy for doctors, and Japanese oncology. Dr Sassé trained at Monash, Peninsula and Austin Health, with a breast fellowship at Monash Health. She completed a Japanese-language observership at the National Cancer Center Hospital, Tokyo, has presented her research in Japanese at international conferences, and is raising her two children bilingually in Japanese and English. Dr Sassé campaigned successfully for Ahpra to reduce registration fees by 30% for doctors on parental and protected leave, and continues to lobby for pro-rata fees. Her prospective study of metastatic breast cancer multidisciplinary meetings, published in *The Breast*, received COSA's Best of the Best Award for Clinical Medicine and led two interstate centres to establish metastatic breast MDMs of their own. She co-convened the 2025 PCPA Cancer Summit, sits on the PCPA Emerging Leaders Board, wrote the *PCPA Practice Handbook Launching Your Practice: A Roadmap for Early-Career Cancer Clinicians*, and is a Director of AMA Victoria.



Professor Shankar Siva

Professor Shankar Siva is the clinical lead of the Cyberknife Centre at 5D in Melbourne, and is a VMO at Icon Cancer Centre. He leads the stereotactic body radiotherapy (SABR) service at the Peter MacCallum Cancer Centre, and is an internationally recognized leader in the field, having designed and led several practice-changing international clinical trials investigating SABR. He has over 350 peer reviewed publications, and \$30 million in competitive grant funding. His current research focused on high-tech radiotherapy delivery, in the context of immunotherapy combinations, lung cancer, oligometastatic disease, kidney cancer and prostate cancer.



Associate Professor Christopher Steer

Assoc Professor Christopher Steer is a leading Australian medical oncologist at Border Medical Oncology, Albury Wodonga Regional Cancer Centre, and an Associate Professor at UNSW. He completed oncology training in Melbourne and a clinical fellowship in London, specialising in geriatric oncology and gynaecological cancers. Professor Steer champions access to clinical trials and cancer care for regional and older patients. He leads research nationally, co-chairs the Victorian Regional Trials Network ReVitalise Project, and has contributed to major oncology organisations including SIOG, COSA, and PCPA, where he is President. A member of the MOGA Oncology Drugs Working Group, Professor Steer promotes oncology innovation in all cancer care.



Associate Professor Colman Taylor

Colman Taylor is Chief Vision Officer at HTANALYSTS and an Associate Professor in Health Economics at UNSW. His work sits at the intersection of health technology assessment, economic modelling, and policy design, with a focus on timely patient access. He advises NFPs, industry, and clinical groups on reimbursement strategy and system design, with a particular interest in how HTA frameworks can evolve to better support timely access to innovation while maintaining rigour.



Mr Harry Thomas

I am a retired Information Technology Executive.

I have navigated significant health issues, care and recovery. Also, someone who has made informed decisions across the cancer pathway, from prevention and diagnosis through to treatment and support services. For over 15 years I have been a board director in health services, with a deep understanding of how systems work in practice.

I am a consumer representative from the Regional Trials Network – Victoria, advocating for equitable access and outcomes for regional and rural patients and helping bridge the gap between metropolitan and regional trial participation.

I am Co-Chair the Statewide Consumer-led Research Program, a Cancer Consumer-led Research Partnership bringing together a group of lived experience leaders (consumers) and five partner organisations with objectives of:

- Amplifying lived experience leaders across Victoria through a statewide partnership model
- Conduct a consumer-led research study, including a scoping review and a longitudinal qualitative study
- Co-design and deliver an immersive masterclass, Lead from Lived Experience: Enhancing Cancer Care.





Professor Jeanne Tie

Professor Jeanne Tie is a consultant medical oncologist and heads the Lower GI Medical Oncology Program at Peter MacCallum Cancer Centre, and Senior Research Fellow at WEHI. Following her fellowship at the Royal Melbourne Hospital and research higher degree at the Ludwig Institute for Cancer Research (University of Melbourne), she has built a research career focused on colorectal cancer therapeutic trials and the clinical application of ctDNA. Her 2016 Science Translational Medicine paper, recognised by ASCO as a major advance, showed ctDNA could detect residual disease after surgery, leading to the practice-changing DYNAMIC trial (NEJM, 2022). She has published 170+ papers with 23,000+ citations, chairs the GI Cancer Trials Lower GI Working Party, and serves on the ESMO Colorectal Guideline Panel and ARCAD steering committee.



Dr Paul Viray

Dr Paul Viray is a dual qualified medical oncologist and geriatrician. He is one of the PCPA's emerging leaders and is the current chair of the national Geriatric Oncology Community of Practice for the Clinical Oncology Society of Australia (COSA). He was part of the expert working group that developed the Optimal Care Pathway for Older People with Cancer now readily available as a resource for cancer clinicians. He trademarked the Viray-CGA (a cancer specific Comprehensive Geriatric Assessment) and is Clinical Lead for Geriatrics and Geri-Onc Research at Cabrini Health in Victoria, where he is establishing a prospective geriatric oncology registry database."



Professor Robyn Ward

Professor Robyn Ward AM (MBBS, PhD, FRACP, FAHMS, FQA) is the current Chair of PBAC and is Deputy Vice-Chancellor (Research and Enterprise) and Senior Vice-President of Monash University. An academic leader, cancer researcher and medical oncologist, she has contributed immensely to the development of Commonwealth and NSW health policy, in addition to her pioneering work on the concept of epigenetic changes. Professor Ward was awarded a Member of the Order of Australia (AM) for significant service to medical research and patient care in the field of oncology. She is an ex-officio member of the PBAC Drug Utilisation Subcommittee (DUSC) and the PBAC Economic Subcommittee (ESC), as well as the former Chair of the Medical Services Advisory Committee (MSAC). Professor Ward has extensive experience in health technology assessment and provides expertise in the fields of medical oncology and cancer genetics.



Professor Desmond Yip

Professor Desmond Yip is a Senior Staff Specialist in Medical Oncology at The Canberra Hospital and Professor at the Australian National University School of Medicine and Psychology. He is the present Chair of the Clinical Oncology Society of Australia Global Oncology Group and a member of the American Society of Clinical Oncology Asia Pacific Regional Council. He is the present Treasurer of the Private Cancer Physicians of Australia and a Director of National Capital Medical Specialists a private haematology/medical oncology practice in the ACT.



SPONSORS



We welcome back our valued members and industry partners.

Platinum Sponsor

abbvie

Gold Sponsor

AstraZeneca

MERCK

Silver Sponsors

astellas

Bristol Myers Squibb®

GILEAD | Kite

GSK

Lilly
A MEDICINE COMPANY

MEDISON

MSD

Roche

Bronze Sponsors

BAYER

GenesisCare
Experts in cancer care

ICON
CANCER CENTRE

IPSEN

medow

NUTRICIA
Fortisip®
Compact Protein

Ramsay
Health Care

Partners

Fletcher | Clarendon

SCIENCETOLIFE

Platinum

abbvie

Abbvie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, and advocates to enable greater access to innovative medicines, driving outcomes for the health of all Australians. AbbVie is committed to tackling the toughest, most difficult-to-treat cancers in the world with high unmet needs. www.abbvie.com.au



Gold



AstraZeneca

AstraZeneca has been present in Australia and New Zealand for more than 60 years.

AstraZeneca is a global, science-led biopharmaceutical company engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians and New Zealanders. Our focus areas include Oncology; Cardiovascular, Renal and Metabolism (CVRM); and Respiratory and Immunology (R&I).

<https://www.astrazeneca.com.au/>



Merck

We are Merck, a vibrant science and technology company.

Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.

The passion of our curious minds makes a positive difference to millions of people's lives every day.

In Healthcare, we are here for people at every step, helping create, improve and prolong life. We discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. We enable people to achieve their dream of becoming parents and we support people with endocrine conditions.

Everything we do is fuelled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and continues to inspire us.

Visit: www.merck.com.au. Follow: LinkedIn and X.

COMPANY BIOS (CONT)



astellas

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.



Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients' lives through science.



Gilead / Kite

Gilead Sciences has pursued and achieved breakthroughs in medicine for more than three decades preventing and treating diseases, including HIV, viral hepatitis, COVID-19 and cancer. Kite, a Gilead company is a global cell therapy leader, treating more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network globally.

COMPANY BIOS (CONT)

Silver



GSK

We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

We get ahead of disease by preventing and treating it with innovation in vaccines and specialty medicines. At the heart of this is our R&D focus on the science of the immune system and advanced technologies, and our world-leading capabilities in vaccine and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology.

In Australia, we employ approximately 600 Australians in many areas of expertise, from graduates to senior managers. We have committed to accelerate our progress on inclusion and diversity, and seek to make a meaningful and lasting contribution to reconciliation.

We have ambitious environmental sustainability goals in both climate and nature: aiming to have a net zero impact on climate by 2030 and a net positive impact on nature by 2030.

For more information visit au.gsk.com.

Date of approval: January 2025

CL Code: PM-AU-DST-COCO-250001



Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com/au or follow us on [LinkedIn](#), [Instagram](#) and [YouTube](#).

Silver



Medison

Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets, with presence in Central and Eastern Europe, Canada, Latin America, Asia Pacific, Australia and Israel. Medison is the first to create a global commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of global partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.

To learn more visit www.medisonpharma.com.



MSD

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

For more information, visit "www.msd-australia.com.au."

Silver



Roche

A healthier future - that's what drives us. Throughout our 128-year history, Roche has grown into one of the world's largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.

Our commitment to our people, partners, stakeholders and, most importantly, patients remains as strong as it was on the first day of our journey.

At Roche, we are doing now what patients need next. We have a global ambition to deliver 20 transformative medicines by 2030, addressing diseases with the highest societal burden. Our focus is on end-to-end investment in 11 diseases across 5 therapy areas which account for the bulk of global disease burden: oncology & haematology, neurology, ophthalmology, immunology and cardiovascular-metabolism.

With a heritage in respect for a healthy planet, Roche's sustainability approach supports the UN Sustainable Development Goals. We are committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.



Bronze



Bayer AG (Global)

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

Bayer has had a presence in Australia and New Zealand since 1897 and 1981 respectively and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. Locally, Bayer employs around 600 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity.

For further information visit www.bayer.com.au or bayer.co.nz



GenesisCare

GenesisCare – experts in cancer care

GenesisCare is a proudly Australian-run cancer care provider, specialising in radiation therapy with a growing footprint in medical oncology, theranostics and personalised medicine. Our relentless pursuit for better care is reflected in our modern treatment techniques, technology and contemporary service experience. Our dedicated doctors and research team partner globally to be first movers in bringing clinical innovations to patients close to home. Around 30,000 people a year entrust us with their care across 50 locations nationally. For more information, visit www.genescare.com.

Bronze



ICON

Empowering clinicians to deliver world class cancer care, close to home

Icon Cancer Centre is proud to support the Private Cancer Physicians of Australia (PCPA) and the important role they play in advancing cancer care nationwide.

As part of Icon Group - Australia's largest dedicated provider of cancer care, we operate 45 centres (and growing) across metropolitan, outer-metro and regional communities, with almost half located in regional areas. Our mission is to empower clinicians to deliver the best possible care, closer to home. Since 2017, our footprint has doubled, significantly increasing access in underserved regions.

Patients are supported by cancer care coordinators, specialist nurses in prostate, melanoma and bowel cancer, and our award-winning survivorship program. This coordinated approach ensures treatment is seamlessly integrated with ongoing support at every stage of care.

We deliver this through a national network of Icon Cancer Centre, day hospitals and radiation oncology centres, backed by the expertise of Slade Pharmacy and Slade Health. Together, our services provide an integrated cancer care experience tailored to each patient's needs.

Icon's 250 plus internationally recognised specialists provide exceptional private cancer care, supported by the infrastructure, technology, and multidisciplinary teams needed to deliver timely, personalised treatment with no wait list for patients.

Our centres offer access to leading treatments and technology, including immunotherapy, advanced radiation therapy techniques, and emerging innovations such as Theranostics, Gamma Knife, and CyberKnife, enabling more targeted and effective treatment options.



IPSEN

Ipsen provides specialty medicines to Healthcare Professionals and their patients suffering from debilitating diseases.

At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals.

Ipsen Pty Ltd is the Australian affiliate of a global biotech company.

CONFERENCE SESSION

See Medow at the PCPA Cancer Summit



Meet the leading doctor behind the AI, and see how Medow is built by specialists, for specialists.



SPECIALIST-GRADE AI SCRIBE

PLENARY 1

The Future of the AI-enabled Specialist Clinic in ANZ

WHEN 29 August 2026 · Session at 10.05 am

STREAM Innovation in Real-World Private Practice



PRESENTED BY

Dr Daniel Cheng

In-house specialist, Medow Health

Dr Cheng works directly alongside Medow's AI engineers, making sure the AI produces notes and letters that sound right for oncology and haematology. His session traces AI in specialist practice from general scribes, to models built specifically for these fields, to where it heads next — worth attending if you want a view of what is coming and how AI is expanding across the whole practice.

"Everyone in our practice loves using Medow. The AI is very effective for oncology and haematology workflows."



Prof. Desmond Yip

Oncologist, National Capital Medical Specialists

"Medow Health have been fantastic. Their team made our move from external dictation to AI seamless."



Joanna Clegg

Practice Manager, Precision Haematology



OFFER FOR PCPA MEMBERS

Medow is offering PCPA members **two months of credit** when you book a demo — fifteen minutes, using your own workflow.

medowhealth.ai · scan to book

Bronze



Nutricia

Nutricia is a leader in specialised medical nutrition, dedicated to supporting people with disease-related malnutrition and complex health needs. In oncology care, Nutricia provides evidence-based nutritional solutions to help patients maintain strength and nutritional status, including Fortisip® Compact Protein, a high-protein oral nutritional supplement designed for cancer patients. To learn more or request for samples of Fortisip® Compact Protein sent to your clinic, please visit here: <https://nutricia.com.au/adult/clinical-conditions/oncology/#> We look forward to supporting you and your patients with evidence-based nutritional solutions.



Ramsay
Health Care

Ramsay Health Care

Ramsay Health Care and PCPA announce inaugural partnership in private cancer care
Ramsay Health Care is pleased to announce its first partnership with the Private Cancer Physicians of Australia (PCPA) a collaboration reflecting a shared commitment to high-quality, coordinated cancer care within the private sector and to supporting the physicians who deliver it. Ramsay operates Australia's largest private hospital networks, providing cancer services across 50 locations. Our facilities support patients throughout the full continuum of care, from diagnosis and staging through active treatment, survivorship and supportive care. Ramsay along with our partners provides medical oncology, surgical oncology, radiation oncology supported by diagnostics, allied health and multidisciplinary coordination.

This breadth allows Ramsay to care for patients across the entire spectrum of cancer treatment. Our model prioritises continuity and integration: coordinated pathways connecting oncology, surgical, nursing, allied health and supportive care around each patient. For visiting medical officers, this provides access to the infrastructure, theatre capacity and clinical teams required to deliver contemporary oncology care.

The partnership with PCPA establishes a formal basis for collaboration with the private oncology physician community. Through it, both organisations intend to share clinical insight, strengthen models of care, and support the private sector's role in improving timely access to cancer treatment. Ramsay is committed to working constructively with PCPA and its members, and regards this inaugural collaboration as an important step we look forward to developing further.

For further information about Ramsay's cancer services or the PCPA partnership, please contact Oncology Service Line Director Katie Sharkey via SharkeyK@ramsayhealth.com.au

Thank you to:



Breast Cancer Network Australia

BCNA Breast Cancer Network Australia (BCNA) is the peak national organisation for Australians personally affected by breast cancer. We support, inform, represent and connect people whose lives have been affected by breast cancer. We work to ensure that Australians diagnosed with breast cancer receive the very best care, treatment, and support. BCNA represents more than 250,000 Australians who have been affected by breast cancer



Partner



Fletcher Clarendon is a boutique firm specialising in providing legal support to clients in the medical and dental industry. We pride ourselves on our firm philosophy of excellence in everything we do.

This philosophy has seen us become the legal adviser to thousands of clients who trust us to look after their legal needs at every stage of their professional and personal journey.

As skilled general commercial lawyers, we can help you with:

1. the beginning of your private practice including all legal work associated with establishing your new practice such as structure advice, structure establishment and the preparation of all associated documentation (such as service agreements, employee contracts, equity holder agreements, associateship agreements and lease agreements);
2. the growth phase of your private practice including admissions, business acquisitions and M&A activity; and
3. the eventual wind down of your journey including exits and ultimate sale events.

We are also well versed in broader complex business transactions and our litigation team are ready to assist if a dispute ever arises.

On a personal level, our estate planning and conveyancing team are ready to help with personal legal matters.

We look forward to working with you! <https://www.fletcherclarendon.com.au/>



ScienceToLife

ScienceToLife is a leading education partner for organisations across the life sciences sector, renowned for providing tailored learning experiences and virtual medical education services. ScienceToLife collaborates with a wide range of industry partners, including the Private Cancer Physicians of Australia (PCPA), to deliver accessible, evidence-based education, coaching, and networking. Our team integrates advanced digital tools to support continuous professional development, career progression, and the practical application of new data and best practices in medicine.

At the helm of ScienceToLife are two accomplished leaders: Sandra Owens, CEO and Rose Brown, COO. Sandra brings over 20 years of executive experience, having held senior positions in top global pharmaceutical companies such as AstraZeneca, Sanofi, and Merck. Her leadership is defined by a vision for innovative education that delivers oncology treatments faster, paired with a deep passion for mentoring and building high-performing teams. Sandra's career spans business transformation and the delivery of patient and commercial outcomes, positioning ScienceToLife as a platform for growth and impact in science education.

Rose, ScienceToLife's COO, is an expert in developing virtual learning tools and clinical program management, with two decades of experience in companies like Eli Lilly and Sanofi. Rose is known for her solution-focused approach and her strong network among key influencers in Australia and New Zealand. Her expertise in product launches, market analysis, and public health drives ScienceToLife's quality outcomes and successful educational programs.



Who Are We?

ClinicCounsel is a subscription legal service made for medical professionals, offering simple pricing and unlimited expert advice. Whether you're starting out, own an established or growing private practice, or are part of a group practice, Clinic Counsel takes the stress out of legal support.

Our Difference



No Surprises

Fixed monthly pricing, so you can call for advice without worrying about the cost.



Expert Understanding

A legal team who already knows your practice, so you're never repeating yourself.



Proactive Support

Ongoing guidance that stops problems before they start.

Clinic Counsel is presented by
Fletcher Clarendon and
trusted by medical
professionals for over 15 years.

Fletcher || **Clarendon**

Have a Question?

Please email usatadmin@fletcherclarendon.com.au or visit
our website cliniccounsel.fletcherclarendon.com.au



PCPA's Strategic Alliance Partners

abbvie

AstraZeneca 

 **GenesisCare**
Experts in cancer care

 **Gordon Legal**
IT'S PERSONAL

GSK

 **LifeStrands**
Empowering lives with Genomics

 **Lilly**
A MEDICINE COMPANY

 **maurice
blackburn
lawyers**

 **MSD**

 **NOVARTIS**

 **Ramsay**
Health Care

 **Roche**

Cellular Therapies Alliance Partners

 **Bristol Myers Squibb®**

Johnson & Johnson

PCPA EXECUTIVES AND BOARD

**President**

A/Professor Christopher Steer
Medical Oncologist,
Albury Wodonga Regional
Cancer Centre

**Treasurer**

Professor Desmond Yip
Medical Oncologist
The Canberra Hospital & National
Capital Medical Specialists

**QLD State Director**

Dr Ian Irving
Clinical Haematologist,
Icon Group Medical Director

**Secretary & Chair of Education**

Professor Stephen Clarke OAM
Medical Oncologist,
Director of Cancer Services NSLHD
Professor of Medicine, University of
Sydney

**VIC State Director**

Dr Cameron McLaren
Medical Oncologist,
St John of God, Berwick

**NSW/ACT State Director**

Dr Anupriya Agarwal
Medical Oncologist
Prince of Wales Private & Mater
Hospital

**Emerging Leaders Director**

Dr Amy Davies
Medical Oncologist
Epworth Freemasons &
SJOG Bendigo

**WA State Director**

Dr Arman Hasani,
Medical Oncologist,
Joondalup Private Hospital

**TAS State Director**

Dr Sunit Sarkar
Medical Oncologist,
Icon Cancer Centre,
Royal Hobart Hospital

**SA/NT State Director**

Dr Tony Michele
Medical Oncologist,
North Adelaide Oncology

**Rural Representative**

Dr Adam Boyce
Medical Oncologist,
St Vincents Lismore

**Radiation Oncology Director**

Dr Evan Ng
Radiation Oncologist
Fiona Stanley Hospital

**Haematology Director**

Assoc Professor Costas Yannakou
Clinical Haematologist
Epworth HealthCare



EMERGING LEADERS BOARD

**Emerging Leaders Director****Dr Amy Davies**

Medical Oncologist
Epworth Freemasons & SJOG Bendigo
Melbourne, Victoria

**Dr Belinda 'Belle' Sassé**

Medical Oncologist
Locum, Australia-wide
Based in Melbourne, Victoria

**Dr Paul Viray**

Medical Oncologist / Geriatrician
Clinical Lead for Geriatrics and Geri-Onc
Research
Cabrini Health, Melbourne, Victoria

**Dr Amanda Goh**

Clinical and Laboratory Haematologist
Mater Pathology, QML Pathology &
Princess Alexandra Hospital, QLD

**Dr Teng Yik Hoo**

Advanced Trainee, Medical Oncology & Nuclear
Medicine.
Fiona Stanley Hospital
Perth, WA

**Dr Kristyn Langworthy**

Medical Oncology trainee
Palliative care consultant
Sir Charles Gardiner hospital, WA

**Dr Helena Sim**

Medical Oncologist
Albury Wodonga Regional
Cancer Centre, Victoria

**Dr Likhitha Sudini**

Medical Oncology Advanced Trainee/
Geriatrics Advanced Trainee
Sydney, NSW



“Our **Emerging Leaders** are pivotal to the future of cancer care in Australia.”

PCPA President
A/Prof Christopher Steer

Become a Member

Are you a cancer physician working in (or considering) private practice and not yet a member?

The PCPA offers its members professional support, networking opportunities, a forum for the exchange of knowledge and an opportunity to be part of the decision making process to help shape the future of private cancer medicine in Australia.

If you wish to join PCPA, visit our website or contact the PCPA Secretariat on pcpa@amaq.com.au or phone (07) 3872 2234.



Join online: www.pcpa.org.au/memberships/register/



Contact:

Jennifer Burgess, PCPA Secretariat

Ph: (07) 3872 2234 | M: 0411 052 722

E: j.burgess@amaq.com.au

W: www.pcpa.org.au